Cognitive disorder
Conditions
Interventions
Treatment group:For the first 4 weeks, 4.6 mg. If no adverse reactions occur during the first 4 weeks of treatment, it is considered that the patient can tolerate it. If tolerated, 9.5 mg can be admin
if not tolerated, maintain at 4.6 mg.
Control group:Cholinesterase inhibitors such as rivastigmine patches have not been used.
Sponsors
Hangzhou Normal University Affiliated Hospital
Eligibility
Sex/Gender
All
Age
40 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age >=40 years old; 2. Meet the corresponding diagnostic criteria for cognitive impairment and be evaluated by the ADAS-cog scale; 3. Have the ability to walk independently and be compatible with wearable devices Gait assessment of the equipment; 4. The patient or their family member signs the informed consent form.
Exclusion criteria
Exclusion criteria: 1.Currently using cholinesterase inhibitors or having adjusted to other cognitive-improving drugs within the past three months; 2. Combined with severe mental disorders or serious internal diseases, unable to cooperate with the assessment; 3. Known allergy to Risamin/carbapatine, other carbamate derivatives or excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ADAS-cog;Gait; | — |
Countries
China
Contacts
Public ContactDanning Lou
Hangzhou Normal University Affiliated Hospital
Outcome results
None listed